Fermentation by Rhizopus spp. has been used as a traditional medicine for treating various inflammatory diseases. Allergic asthma is a chronic respiratory disease that is caused by an exaggerated immune response. This study was conducted to ascertain the anti-inflammatory effects of Rhizopus spp. fermentation extract (RU) on a mouse model of ovalbumin (OVA)-induced asthma. The animals were intraperitoneally injected OVA on day 1 and 7, followed by OVA intranasal inhalation on days 14 to 18. The animals were treated daily with RU (100 and 200 mg/kg) by oral gavage from day 18 to day 23. RU significantly decreased eosinophilia and the production of inflammatory cytokines and OVA specific immunoglobulin E in animals with asthma, along with reducing airway inflammation and mucus secretion in lung tissue. Histological changes in the lungs and levels of inflammatory mediators of allergic airway inflammation were evaluated. The regulatory effects of RU on type 2 helper T (Th2) cell activation were investigated. RU administration attenuated asthmatic changes such as inflammatory cell infiltration and mucus production, decreased the levels of Th2-related cytokines, and reduced Th2 cell activation. Administration of RU effectively reduced allergic responses in asthmatic mice, which is associated with regulating Th2 cell activation and differentiation. These results indicate that RU can attenuate the respiratory symptoms of asthma.

Iron deficiency is known to be a common nutritional disorder in many countries, especially among children, women of childbearing age and pregnant women. SUNACTIVE Fe-P80 is a new type of iron supplement that applies nanotechnlateology for the purpose of overcoming the disadvantages of food supplements. This study was conducted to investigate the potential adverse effects of a 28-day repeated oral dose of SUNACTIVE Fe-P80 in rats. SUNACTIVE Fe-P80 was administered once daily by gavage to Sprague-Dawley rats for 28 days at doses of 0, 500, 1,000, and 2,000 mg/kg/day. Additional recovery groups from the control and highdose groups were observed for a 14-day recovery period. At the scheduled termination, the animals were sacrificed, their organs weighed, and blood samples collected. There were no treatment-related effects in the context of clinical signs, body weight, food intake, ophthalmoscopy, urinalysis, necropsy findings, organ weights, and hematologic, serum biochemical and histopathological parameters at any dose tested. Under the present experimental conditions, the no-observed-adverse-effect level of SUNACTIVE Fe-P80 was ≥ 2,000 mg/kg/day in both the sexes, and no target organs were identified. Thus, the results suggest that SUNACTIVE Fe-P80 is relatively safe, as no treatment-related adverse effects were observed following a 28-day repeated oral dose experiment.